drugset / Trial / NCT01788501

Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease

NCT01788501

Phase 2/3 Completed 50 enrolled Seoul National University Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study aims to compare efficacy and safety of tacrolimus/methotrexate with cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic hematopoietic stem cell transplantation patients.

Timeline

Start
2011-11
Primary completion
2017-03-01
Completion
2017-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 3 mg/kg Intravenous
Subject Methotrexate Small molecule 10 mg/m2 Intravenous
Subject Tacrolimus Small molecule 0.03 mg/kg Intravenous